Contract Development and Manufacturing Organization (CDMO) Outsourcing Market Size, Share, Growth, and Industry Analysis, By Type (CMO, CRO), By Application (Pharmaceutical, Academic & Research Institutes, Others), Regional Insights and Forecast to 2035

Contract Development and Manufacturing Organization (CDMO) Outsourcing Market Overview

The global Contract Development and Manufacturing Organization (CDMO) Outsourcing Market size estimated at USD 301473.17 million in 2026 and is projected to reach USD 772874.19 million by 2035, growing at a CAGR of 11.03% from 2026 to 2035.

The Contract Development and Manufacturing Organization (CDMO) outsourcing market market is expanding due to rising pharmaceutical production volumes, increasing biologics demand, and higher outsourcing penetration across drug development stages. More than 58% of pharmaceutical manufacturers outsourced at least one production process in 2025, while biologics accounted for 39% of outsourced projects globally. Over 2,800 active CDMO facilities operated worldwide during 2025, including 920 facilities focused on sterile injectables and biologics. Smallmolecule manufacturing represented 47% of outsourced manufacturing contracts, while cell and gene therapy projects contributed 14% of new outsourcing agreements.

The United States accounted for 41% of global CDMO outsourcing demand in 2025 due to strong pharmaceutical R&D activity, increasing biologics approvals, and expanding clinical trial pipelines. More than 5,600 active drug candidates were under development in the country, with 64% involving outsourced development or manufacturing support. The U.S. biologics outsourcing segment represented 36% of total outsourcing agreements, while oncologyrelated manufacturing projects accounted for 29% of CDMO contracts. Over 480 FDAinspected CDMO production sites were active across the country in 2025.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: More than 68% of pharmaceutical companies increased outsourcing activities, while 54% shifted biologics manufacturing externally and 47% expanded clinicalstage outsourcing partnerships to improve production flexibility and reduce operational burden across drug pipelines.

• Major Market Restraint: Around 39% of manufacturers faced regulatory compliance delays, 33% experienced supply chain disruptions, and 28% reported quality control inconsistencies linked to crossborder manufacturing operations and varying international compliance standards.

• Emerging Trends: Approximately 44% of CDMOs adopted AIenabled production monitoring, 36% integrated continuous manufacturing systems, and 31% expanded cell and gene therapy manufacturing capabilities to support precision medicine development activities.

• Regional Leadership: North America represented 41% of global outsourcing demand, Europe contributed 29%, AsiaPacific accounted for 24%, and Middle East & Africa maintained 6% share through expanding pharmaceutical production investments.

• Competitive Landscape: The top five CDMO providers controlled 46% of global outsourcing agreements, while 58% of midsized pharmaceutical firms preferred multiservice outsourcing partnerships and 34% prioritized biologicsfocused manufacturing providers.

• Market Segmentation: Pharmaceutical applications held 63% market share, academic and research institutes represented 21%, and other applications contributed 16%, while CMO services accounted for 57% and CRO services captured 43% of outsourcing activity.

• Recent Development: More than 32% of major CDMOs expanded biologics facilities during 2024, 26% introduced advanced fillfinish systems, and 18% launched automated manufacturing platforms to increase operational productivity and batch consistency.

Contract Development and Manufacturing Organization (CDMO) Outsourcing Market Latest Trends

The Contract Development and Manufacturing Organization (CDMO) outsourcing market market is witnessing significant transformation driven by biologics manufacturing, advanced therapeutics, and digital production technologies. Biologics represented 39% of outsourced drug manufacturing projects in 2025, while monoclonal antibodies accounted for 24% of biologics outsourcing contracts. Cell and gene therapy manufacturing demand increased by 33%, leading over 140 CDMOs to establish dedicated advanced therapy production suites. Continuous manufacturing systems were implemented by 36% of global CDMO providers, improving production speed by 27% and lowering material waste by 18%.

Singleuse bioprocessing systems gained strong traction, with 48% of biologics facilities integrating disposable technologies to reduce contamination risks and shorten cleaning cycles by 42%. Artificial intelligencebased quality monitoring systems were adopted by 44% of large CDMOs, resulting in 21% lower batch failure rates. Sterile injectable outsourcing increased by 29% due to rising demand for specialty drugs and hospitaladministered therapies.

Contract Development and Manufacturing Organization (CDMO) Outsourcing Market Dynamics

DRIVER

Rising demand for pharmaceuticals and biologics.

The increasing production of pharmaceutical and biologic products remains a major growth driver for the Contract Development and Manufacturing Organization (CDMO) outsourcing market market. More than 21,000 pharmaceutical products were in active development globally during 2025, while biologics accounted for 37% of total drug pipelines. Outsourcing penetration among pharmaceutical companies reached 68%, compared with 52% in 2020. Oncology therapeutics represented 31% of outsourced manufacturing contracts due to increasing demand for targeted therapies and antibodybased medicines.

RESTRAINT

Complex regulatory compliance and quality control standards.

Regulatory compliance challenges continue to restrain growth in the Contract Development and Manufacturing Organization (CDMO) outsourcing market market. Approximately 39% of pharmaceutical companies reported delays associated with regulatory inspections and quality validation requirements. More than 28% of outsourced projects experienced timeline extensions because of documentation inconsistencies or manufacturing deviations. Crossborder manufacturing agreements increased regulatory complexity, with 34% of CDMOs operating facilities across multiple compliance jurisdictions.

OPPORTUNITY

Growth in personalized medicines and advanced therapies.

The rapid expansion of personalized medicine and advanced therapies is creating major opportunities within the Contract Development and Manufacturing Organization (CDMO) outsourcing market market. More than 2,400 gene therapy and cell therapy candidates were under development globally in 2025. Approximately 33% of advanced therapy developers outsourced manufacturing activities due to high equipment costs and technical expertise requirements. CDMOs specializing in viral vector production expanded manufacturing capacity by 29% between 2023 and 2025.

CHALLENGE

Rising operational costs and supply chain disruptions.

Increasing operational expenditures and global supply chain instability remain major challenges for the Contract Development and Manufacturing Organization (CDMO) outsourcing market market. Raw material procurement delays affected 32% of outsourcing projects during 2024 and 2025. Biologic manufacturing materials experienced average leadtime increases of 21%, while transportation delays affected 18% of international pharmaceutical shipments. 

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

Segmentation Analysis

The Contract Development and Manufacturing Organization (CDMO) outsourcing market market is segmented by type and application, with each category contributing distinct operational demand. CMO services represented 57% of outsourcing activity due to rising commercialscale manufacturing requirements, while CRO services accounted for 43% through clinical research and development support. Pharmaceutical applications dominated with 63% share due to increasing drug production volumes and biologics demand. Academic and research institutes contributed 21% through preclinical development partnerships and laboratory outsourcing agreements. Other applications held 16% share due to increasing nutraceutical, veterinary, and specialty healthcare product outsourcing.

By Type

CMO

Contract Manufacturing Organization (CMO) services represented 57% of the Contract Development and Manufacturing Organization (CDMO) outsourcing market market in 2025. More than 61% of pharmaceutical companies outsourced commercial drug manufacturing to CMOs to improve production flexibility and reduce infrastructure expenses. Sterile injectable production accounted for 28% of CMO contracts, while oral solid dosage manufacturing represented 34% of agreements. Biologics manufacturing within the CMO segment increased by 31% due to expanding monoclonal antibody production.

CRO

Contract Research Organization (CRO) services accounted for 43% of the Contract Development and Manufacturing Organization (CDMO) outsourcing market market in 2025. Clinical trial management represented 37% of CRO activities, while preclinical research services contributed 24% of outsourcing demand. More than 58% of biotechnology companies outsourced clinical development processes to CRO providers to reduce research timelines and improve trial management efficiency.Phase II and Phase III clinical trials accounted for 46% of CRO contracts globally. Decentralized clinical trial adoption increased by 28%, supported by digital patient monitoring technologies and remote data collection systems.

By Application

Pharmaceutical

The pharmaceutical segment held 63% share of the Contract Development and Manufacturing Organization (CDMO) outsourcing market market in 2025. More than 68% of pharmaceutical manufacturers outsourced at least one stage of product development or commercial manufacturing. Smallmolecule drugs accounted for 47% of pharmaceutical outsourcing contracts, while biologics represented 39%. Injectable products contributed 26% of outsourced pharmaceutical production demand.

Academic & Research Institutes

Academic and research institutes accounted for 21% of the Contract Development and Manufacturing Organization (CDMO) outsourcing market market in 2025. More than 3,200 research collaborations between universities and CDMOs were active globally, supporting preclinical testing, biologics development, and clinical trial material manufacturing. Outsourced laboratory testing represented 36% of academic outsourcing activities. 

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Contract Development and Manufacturing Organization (CDMO) Outsourcing Market Regional Outlook

The Contract Development and Manufacturing Organization (CDMO) outsourcing market market demonstrates strong regional variation based on pharmaceutical manufacturing infrastructure, regulatory systems, and biotechnology investments. North America held 41% share due to advanced biologics production and extensive pharmaceutical R&D activity. Europe represented 29% through strong specialty drug manufacturing and established compliance systems. AsiaPacific accounted for 24% due to expanding pharmaceutical exports and lower manufacturing costs. Middle East & Africa contributed 6% through growing healthcare investments and regional pharmaceutical production initiatives.

North America

North America held 41% share of the Contract Development and Manufacturing Organization (CDMO) outsourcing market market in 2025. The United States accounted for 87% of regional outsourcing demand due to advanced pharmaceutical manufacturing infrastructure and high biologics development activity. More than 480 FDAinspected CDMO facilities operated across the region, including 160 biologicsfocused manufacturing plants.Biologics outsourcing represented 36% of regional outsourcing agreements, while oncology therapeutics accounted for 29% of manufacturing projects. 

Europe

Europe accounted for 29% of the Contract Development and Manufacturing Organization (CDMO) outsourcing market market in 2025. Germany, Switzerland, France, and the United Kingdom represented more than 68% of regional outsourcing demand due to strong pharmaceutical manufacturing capabilities and biologics expertise. More than 720 active CDMO facilities operated across Europe during 2025.Biologics manufacturing represented 34% of European outsourcing agreements, while oral solid dosage production accounted for 32%. Oncology therapeutics contributed 27% of outsourced manufacturing projects.

AsiaPacific

AsiaPacific represented 24% of the Contract Development and Manufacturing Organization (CDMO) outsourcing market market in 2025. China, India, Japan, and South Korea accounted for 79% of regional outsourcing activity due to expanding pharmaceutical manufacturing infrastructure and costefficient production capabilities. More than 1,050 CDMO production facilities operated across AsiaPacific during 2025.China represented 38% of regional outsourcing demand through strong active pharmaceutical ingredient and biologics manufacturing capabilities. India contributed 27% due to generic drug production and increasing injectable manufacturing capacity.

Middle East & Africa

Middle East & Africa accounted for 6% of the Contract Development and Manufacturing Organization (CDMO) outsourcing market market in 2025. Saudi Arabia, the United Arab Emirates, South Africa, and Egypt represented more than 71% of regional outsourcing activity due to healthcare investments and pharmaceutical manufacturing expansion programs.Regional pharmaceutical production capacity increased by 18% between 2023 and 2025, while outsourcing demand for generic drug manufacturing expanded by 21%. Injectable pharmaceutical production represented 26% of regional CDMO agreements.

List of Top Contract Development and Manufacturing Organization (CDMO) Outsourcing Market Companies

• WuXi Biologics
• BioXcellence
• Patheon
• Catalent Inc
• Aenova Holding GmbH
• Almac Group Ltd
• FAMAR
• FAREVA SA
• Recipharm AB
• Siegfried Holding AG
• Lubrizol Corporation

List of Top tow Companies Market Share

• Lonza held approximately 11% share of global CDMO outsourcing agreements in 2025, supported by more than 20 manufacturing facilities worldwide and over 300 active biologics development partnerships.

• Thermo Fisher Scientific Inc accounted for nearly 9% market share through integrated pharmaceutical manufacturing services, operating more than 55 production and laboratory facilities supporting clinical and commercial drug manufacturing.

Investment Analysis and Opportunities

Investment activity within the Contract Development and Manufacturing Organization (CDMO) outsourcing market market accelerated significantly during 2025 due to increasing pharmaceutical outsourcing demand and advanced therapy manufacturing expansion. More than 240 largescale manufacturing investment projects were announced globally between 2023 and 2025. Biologics facility investments accounted for 42% of total expansion projects, while sterile injectable production represented 23%.

North America attracted 39% of global CDMO infrastructure investments due to strong biotechnology activity and increasing biologics approvals. AsiaPacific accounted for 31% of expansion investments through costefficient manufacturing projects and active pharmaceutical ingredient production growth. More than 140 facilities introduced modular cleanroom systems to support personalized medicine manufacturing.Cell and gene therapy manufacturing investments increased by 34%, while viral vector production capacity expanded by 27%. Artificial intelligencebased manufacturing systems were integrated into 44% of newly constructed CDMO facilities to improve process monitoring and quality control efficiency.

New Product Development

New product development within the Contract Development and Manufacturing Organization (CDMO) outsourcing market market focused heavily on biologics, advanced therapies, and digital manufacturing technologies during 2025. More than 1,200 biologic drug candidates entered outsourced development programs globally. Monoclonal antibodies accounted for 28% of newly outsourced product development projects, while cell and gene therapy candidates represented 17%.

Continuous manufacturing systems were introduced in 36% of newly upgraded production facilities, reducing manufacturing cycle times by 24%. More than 48% of biologics manufacturers adopted singleuse bioprocessing systems for faster batch transitions and contamination control improvements. Artificial intelligenceenabled predictive maintenance systems reduced equipment downtime by 18% across large CDMO production sites.mRNA manufacturing capabilities expanded significantly, with 22% more CDMOs adding specialized mRNA production suites between 2023 and 2025.

Five Recent Developments (20232025)

• WuXi Biologics expanded biologics manufacturing capacity by 24% during 2024 through the addition of multiple singleuse bioreactor systems supporting monoclonal antibody production.

• Lonza increased cell and gene therapy production infrastructure by 21% in 2025, adding advanced viral vector manufacturing suites and automated quality control systems.

• Thermo Fisher Scientific Inc upgraded sterile injectable manufacturing operations in 2024, improving fillfinish production efficiency by 18% through automated packaging technologies.

• Catalent Inc expanded highpotency active pharmaceutical ingredient manufacturing capacity by 17% in 2023 to support rising oncology therapy production requirements.

• Recipharm AB introduced continuous manufacturing technologies across selected European production sites during 2025, reducing batch processing timelines by 16% and lowering operational waste generation.

Report Coverage of Contract Development and Manufacturing Organization (CDMO) Outsourcing Market

The report on the Contract Development and Manufacturing Organization (CDMO) outsourcing market market provides comprehensive analysis of manufacturing outsourcing trends, biologics production expansion, and pharmaceutical development activities across global regions. The study evaluates more than 2,800 active CDMO facilities operating worldwide and examines outsourcing penetration across biologics, sterile injectables, oral solid dosage forms, and advanced therapies.

The report analyzes segmentation by type, including CMO and CRO services, while covering applications across pharmaceutical manufacturers, academic institutions, and specialty healthcare product providers. More than 40% of the report coverage focuses on biologics outsourcing due to rising monoclonal antibody, cell therapy, and gene therapy production demand.Regional assessment includes North America, Europe, AsiaPacific, and Middle East & Africa, with analysis of manufacturing capacity, outsourcing agreements, regulatory compliance systems, and investment activity.

Contract Development and Manufacturing Organization (CDMO) Outsourcing Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 301473.17 Billion in 2026
Market Size Value By	USD 772874.19 Billion by 2035
Growth Rate	CAGR of 11.03% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : CMO CRO By Application : Pharmaceutical Academic & Research Institutes Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample